Literature DB >> 1486903

Potency of vascular risk factors as the basis for antihypertensive therapy.

W B Kannel1.   

Abstract

Hypertension is a powerful predisposing risk factor for cardiovascular disease at all ages and in both sexes. Epidemiological assessment indicates the largest risk ratios for stroke and congestive heart failure (CHF), but coronary heart disease (CHD) is the most common and most lethal sequela of hypertension. Examination of the risk of cardiovascular sequelae in the hypertensive population indicates that this is not uniform and varies over a 10-fold range, depending on the associated risk factors. Systolic pressure merits greater consideration than the diastole pressure because isolated systolic hypertension is a powerful cardiovascular risk at all ages. Furthermore, recent trials have indicated the benefit of therapy for systolic-based hypertension in the elderly, even using a diuretic, for coronary disease as well as stroke. Persons with hypertension have a high prevalence of associated cardiovascular risk factors, including elevated cholesterol, reduced HDL-C, diabetes, left ventricular hypertrophy (LVH), and obesity. About 9% under the age of 65 years have an associated overt cardiovascular disease; above age 65 about 30% are so afflicted. Each of these risk factors can double the risk associated with hypertension. Because they are so common, a large fraction of the disease sequelae of hypertension is attributable to these associated risk factors. The high risk of coronary disease in hypertensive patients is concentrated in those with a high total/HDL-cholesterol ratio, impaired glucose tolerance, high fibrinogen, ECG abnormalities, and cigarette smokers. Stroke risk in hypertensive persons is concentrated in those with cardiovascular disease, diabetes, atrial fibrillation, LVH and cigarette smoking.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1486903     DOI: 10.1093/eurheartj/13.suppl_g.34

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  5 in total

Review 1.  Drug selection for optimal treatment of hypertension in the elderly.

Authors:  E Shammas; K Dickstein
Journal:  Drugs Aging       Date:  1997-07       Impact factor: 3.923

2.  Efficacy and tolerability of amlodipine in the general practice treatment of essential hypertension in an asian multinational population.

Authors:  S H Taylor; M F Chen; S J Lee; B Koanantakul; J R Zhu; T Santoso; R G Sy; Y T Tai
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

3.  Glucose homeostasis abnormalities among Cameroon patients with newly diagnosed hypertension.

Authors:  Félicité Kamdem; Daniel Lemogoum; Marie-Solange Doualla; Fernando Kemta Lepka; Elvis Temfack; Yvette Ngo Nouga; Caroline Kenmegne; Henry Luma; Michel P Hermans
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-01-02       Impact factor: 3.738

4.  Electrocardiographic left ventricular hypertrophy and mortality in an oldest-old hypertensive Chinese population.

Authors:  Rui Chen; Kunhao Bai; Fanghong Lu; Yingxin Zhao; Yujing Pan; Fang Wang; Luxia Zhang
Journal:  Clin Interv Aging       Date:  2019-09-17       Impact factor: 4.458

5.  Trends and risk factors for non-communicable diseases mortality in Nairobi slums (2008-2017).

Authors:  Gershim Asiki; Damazo Kadengye; Clara Calvert; Marylene Wamukoya; Shukri F Mohamed; Abdhalah Ziraba; Samuel Iddi; Martin Bangha; Frederick Wekesah; Claudious Chikozho; Alison Price; Mia Crampin; Catherine Kyobutungi
Journal:  Glob Epidemiol       Date:  2021-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.